Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies
Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies
复制标题
DOI：
10.1016/j.apradiso.2009.03.103
复制
发表时间：
2009-07-01
影响因子：
1.6
通讯作者：
Ono, Koji
中科院分区：
文献类型：
--
作者：
Kato, Itsuro;Fujita, Yusei;Ono, Koji
为避免复发性头颈部恶性肿瘤对口腔颌面部结构和功能造成严重损害，有必要探索新的治疗方法。硼中子俘获治疗（BNCT）是一种肿瘤细胞靶向放射治疗方法，从2001年至今，我们对26例复发性晚期HNM患者（鳞癌19例，涎腺癌4例，肉瘤3例）进行了42次BNCT治疗。（1）（10）FBPA-PET研究的肿瘤/正常组织B浓度比（T/N比）的结果为SCC：1.8-5.7，肉瘤：2.5-4.0，腮腺肿瘤：2.5-3.7。(2)疗效：CR 12例，PR 10例，PD 3例，NE（未评价）1例。有效率为85%。(3)QCL的改善，如局部病变的严重疼痛、出血和渗出物缓解，PS改善，溃疡消失，覆盖正常皮肤，保留口腔颌面部功能和组织。(4)BNCT术后生存期1-72个月，平均13.6个月。Kaplan-Meier分析6年生存率为24%。(5)大多数病例的不良事件为一过性粘膜炎和脱发;确认了3例骨髓炎和1例脑坏死。这些结果表明，BNCT代表了一种新的和有前途的治疗方法，先进的HNM。(C)2009爱思唯尔有限公司保留所有权利。
It is necessary to explore new treatments for recurrent head and neck malignancies (HNM) to avoid severe impairment of oro-facial structures and functions. Boron neutron capture therapy (BNCT) is tumor-cell targeted radiotherapy that has significant superiority over conventional radiotherapies in principle.We have treated with BNCT 42 times for 26 patients (19 squamous cell carcinomas (SCC), 4 salivary gland carcinomas and 3 sarcomas) with a recurrent and far advanced HNM since 2001. Results of (1) (10)B concentration of tumor/normal tissue ratios (T/N ratio) of FBPA-PET studies were SCC: 1.8-5.7, sarcoma: 2.5-4.0, parotid tumor: 2.5-3.7.(2) Therapeutic effects were CR: 12 cases, PR: 10 cases, PD: 3 cases NE (not evaluated): 1 case. Response rate was 85%. (3) Improvement of QCL such as a relief of severe pain, bleeding, and exudates at the local lesion, improvement of PS, disappearance of ulceration, covered with normal skin and preserved oral and maxillofacial functions and tissues. (4) Survival periods after BNCT were 1-72 months (mean: 13.6 months). Six-year survival rate was 24% by Kaplan-Meier analysis. (5) Adverse-events were transient mucositis and alopecia in most of the cases; three osteomyelitis and one brain necrosis were recognized. These results indicate that BNCT represents a new and promising treatment approach for advanced HNM. (C) 2009 Elsevier Ltd. All rights reserved.